|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Engulfing Bearish||1D||2||Dec 12, 2017|
|Bullish doji Star||1H||2||Dec 13, 2017 15:30|
|Morning Doji Star||1D||4||Dec 08, 2017|
|Three Outside Down||5H||4||Dec 12, 2017 12:30|
|Three Outside Down||1H||4||Dec 13, 2017 13:30|
|Oil & Natural Gas||184.75||186.70||184.25||+0.85||+0.46%||1.20M||09:59:41|
|AVT Natural Products Ltd||56.20||57.30||54.80||+1.85||+3.40%||898.07K||09:59:54|
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.Read More
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.